ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

LIXT Lixte Biotechnology Holdings Inc

2.82
-0.0621 (-2.15%)
04 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Lixte Biotechnology Holdings Inc LIXT 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
-0.0621 -2.15% 2.82 09:00:00
개장가 저가 고가 종가 전일 종가
3.00 2.8735 3.002 2.89 2.8821
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
25/04/202404:25APSMixed Shelf Filing Gives Micro Cap Delayed Boost
28/03/202404:35APSBiotech Steals The Show Following Pre-Clinical Data..
27/03/202421:30GLOBENEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD..
21/03/202421:30GLOBELIXTE Provides Update on Progress with LB-100 as a PP2A..
28/02/202406:59EDGAR2Form 8-K - Current report
27/02/202422:30GLOBEProfessor René Bernards to Present New Pre-Clinical Data on..
27/02/202400:48EDGAR2Form 8-K - Current report
26/02/202422:30GLOBELIXTE Biotechnology Enters into Exclusive Immune Oncology..
29/01/202422:30GLOBEFirst Patient Dosed with LIXTE’s LB-100 and GSK’s..
29/11/202307:21EDGAR2Form 8-K - Current report
14/11/202304:28EDGAR2Form 8-K - Current report
13/11/202322:30GLOBELIXTE Biotechnology Provides Update on Clinical Progress and..
10/11/202307:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
18/10/202306:27EDGAR2Form 8-K - Current report
17/10/202303:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/10/202321:30GLOBELIXTE, Netherlands Cancer Institute, and Oncode Institute to..
11/10/202304:55EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
11/10/202304:47EDGAR2Form DEF 14A - Other definitive proxy statements
09/10/202321:30GLOBELIXTE Biotechnology Holdings Announces the Passing of its..
06/10/202309:39EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
06/10/202309:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202307:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/09/202305:05EDGAR2Form PRE 14A - Other preliminary proxy statements
27/09/202319:15EDGAR2Form 8-K - Current report
27/09/202319:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/09/202321:30GLOBELIXTE Appoints Bas van der Baan as President and Chief..
21/09/202300:20EDGAR2Form 8-K - Current report
20/09/202321:30GLOBELIXTE Biotechnology Announces a Supported Collaborative..
12/08/202305:20EDGAR2Form S-3 - Registration statement under Securities Act of..
09/08/202321:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
22/07/202305:05EDGAR2Form 8-K - Current report
21/07/202305:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
21/07/202305:05GLOBELIXTE Biotechnology Announces Closing of $3.5 Million..
21/07/202300:45EDGAR2Form 8-K - Current report
18/07/202321:00GLOBELIXTE Biotechnology Announces Pricing of $3.5 Million..
17/07/202321:30GLOBEPreclinical Results of LIXTE Biotechnology’s Collaboration..
08/07/202303:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/07/202323:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/07/202323:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/07/202323:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/06/202321:30GLOBELIXTE Biotechnology Holdings, Inc. Regains Compliance with..
07/06/202321:30GLOBELIXTE Biotechnology and the Spanish Sarcoma Group Enroll..
03/06/202301:30GLOBELIXTE Biotechnology Holdings, Inc. Announces 1-for-10..
30/05/202321:30GLOBERecently Published Independent Research Reveals New..

최근 히스토리

Delayed Upgrade Clock